within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL05_FormoterolAndAclidiniumB;

model FormoterolAndAclidiniumB
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.5e-05,
    adminDuration = 600,
    adminMass = 12 / 1000000,
    adminCount = 1,
    Vd = 0.2,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>FormoterolAndAclidiniumBromide</td></tr><tr><td>ATC code:</td><td>R03AL05</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>12</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>200</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1500</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Formoterol and aclidinium bromide is a fixed-dose combination inhalation medication comprising a long-acting beta2-agonist (formoterol) and a long-acting muscarinic antagonist (aclidinium) used in the maintenance treatment of chronic obstructive pulmonary disease (COPD). Both substances act by relaxing airway smooth muscle and inhibiting bronchoconstriction to help maintain open airways. The combination is approved and in current use for COPD management.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic studies directly examining the combination product were found in the literature. Parameters below are estimated based on the published PK parameters of individual drugs (inhaled formoterol and aclidinium) in healthy adults. Model assumes one-compartment kinetics and standard inhalation administration.</p><h4>References</h4><ol><li><p>Lal, C, &amp; Strange, C (2015). Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. <i>Expert opinion on pharmacotherapy</i> 16(3) 427–434. DOI:<a href=\"https://doi.org/10.1517/14656566.2015.1000861\">10.1517/14656566.2015.1000861</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25597386/\">https://pubmed.ncbi.nlm.nih.gov/25597386</a></p></li><li><p>Zhang, H, et al., &amp; Ding, Y (2022). An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. <i>Drugs in R&amp;D</i> 22(1) 35–42. DOI:<a href=\"https://doi.org/10.1007/s40268-021-00374-z\">10.1007/s40268-021-00374-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35133636/\">https://pubmed.ncbi.nlm.nih.gov/35133636</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AL05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end FormoterolAndAclidiniumB;
